The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.
Abstract
Oxidant stress, due to the formation of hydrogen peroxide and oxygen‐derived free radicals, can cause cell damage due to chain reactions of membrane lipid peroxidation. Because the substantia nigra is rich in dopamine, which can undergo both enzymatic oxidation via monoamine oxidase and nonenzymatic autoxidation, hydrogen peroxide and oxyradicals (superoxide anion radical and hydroxyl radical) are generated in this midbrain nucleus. Although proof that oxidant stress actually causes the loss of monoaminergic neurons in patients with Parkinson's disease is lacking, there is a considerable body of evidence from studies in both animals and humans that support the concept. (1) Neurotoxins that selectively destroy the dopaminergic neurons in the nigra, such as 6‐hydroxydopamine and 1‐methyl‐4‐phenyl‐l,2,3,6‐tetrahydropyridine (MPTP), appear to act via oxidant stress. (2) The substantia nigra of patients with Parkinson's disease reveals evidence of oxidant stress by the findings of increased lipid peroxidation and decreased reduced glutathione. (3) Total iron is increased and ferritin is reduced in the substantia nigra pars compacta in patients with Parkinson's disease. This combination suggests that this transition metal is in a low molecular weight form, capable of catalyzing nonenzymatic oxidative reactions, especially the conversion of hydrogen peroxide to hydroxyl radical, which is the most reactive of the oxygen radicals. (4) Neuromelanin, a product of dopamine autoxidation, can serve as a reservoir for iron, promoting the generation of oxyradicals. (5) Antioxidant defense mechanisms appear to be reduced in the parkinsonian substantia nigra with the findings of decreased activities of glutathione peroxidase and catalase. (6) The recent findings of decreased activity of NADH‐CoQ reductase, a mitochondrial complex I enzyme, in substantia nigra and platelets in patients with Parkinson's disease can also be interpreted to be a cause or product of oxidant stress. The identical enzyme abnormality occurs with MPTP toxicity, and this has been associated with increased superoxide anion radical formation. Moreover, mice with increased activity of superoxide dismutase are protected against MPTP toxicity. The evidence favoring the oxidant stress hypothesis is persuasive, but not yet fully established. We believe that this is the best hypothesis available at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxidative stress and inflammation are early events of neurodegenerative diseases [920,944-957]”
In the citing paper
“Iron (and in some cases copper) is also strongly implicated in a variety of neurodegenerative diseases [944,981,945,958,962,950,917,278,43,285,972,141,975-1087].”
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Oxygen radicals and human disease
CROSS, C. E., HALLIWELL, B., BORISH, E. T., PRYOR, W. A., AMES, B. N., SAUL, R. L., McCORD, J. M., & HARMAN, D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-4-526 · Cited by 1,856
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126
Abnormalities of the electron transport chain in idiopathic parkinson's disease
Parker, W. D., Boyson, S. J., & Parks, J. K. (1989) · Annals of Neurology · doi:10.1002/ana.410260606 · Cited by 1,063
DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Cohen, G., Heikkila, R. E., & MacNamee, W. T. T. A. O. D. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42751-8 · Cited by 897
Self-citationPharmacological Actions of 6-Hydroxydopamine
Kostrzewa, R. M., & Jacobowitz, D. M. (1974) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06677-3 · Cited by 817
Alzheimer's Disease: Senile Dementia and Related Disorders
Bellur, S. N. (1979) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1979.03300200059031 · Cited by 803
Parkinson's disease: A disorder due to nigral glutathione deficiency?
Perry, T. L., Godin, D. V., & Hansen, S. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90390-1 · Cited by 753
Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease
Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., Sato, T., Oya, H., Ozawa, T., & Kagawa, Y. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91141-8 · Cited by 739
Schapira, A. H. V., Mann, V. M., Cooper, J. M., Dexter, D., Daniel, S. E., Jenner, P., Clark, J. B., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673
Aging and Extrapyramidal Function
McGeer, P. L., McGeer, E. G., & Suzuki, J. S. (1977) · Archives of Neurology · doi:10.1001/archneur.1977.00500130053010 · Cited by 647
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Tetrud, J. W., & Langston, J. W. (1989) · Science · doi:10.1126/science.2502843 · Cited by 638
Ballard, P. A., Tetrud, J. W., & Langston, J. W. (1985) · Neurology · doi:10.1212/wnl.35.7.949 · Cited by 629
Gibb, W. R., & Lees, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574
Rate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 556
Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains
Sofic, E., Paulus, W., Jellinger, K., Riederer, P., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02017.x · Cited by 524
Distinct Monoamine Oxidase A and B Populations in Primate Brain
Westlund, K. N., Denney, R. M., Kochersperger, L. M., Rose, R. M., & Abell, C. W. (1985) · Science · doi:10.1126/science.3875898 · Cited by 504
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization
Hefti, F., Melamed, E., & Wurtman, R. J. (1980) · Brain Research · doi:10.1016/0006-8993(80)90871-9 · Cited by 501
Halliwell, B. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb01779.x · Cited by 469
AETIOLOGY OF PARKINSON'S DISEASE
Calne, D., & William Langston, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90802-4 · Cited by 469
Przedborski, S., Kostic, V, Jackson-Lewis, V, Naini, A., Simonetti, S., Fahn, S., Carlson, E., Epstein, C., & Cadet, J. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01658.1992 · Cited by 456
Self-citationA Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra
Saggu, H., Cooksey, J., Dexter, D., Wells, F. R., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb11759.x · Cited by 454
Brain Peroxidase and Catalase in Parkinson Disease
Ambani, L. M., Van Woert, M. H., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 402
Dopamine turnover and glutathione oxidation: implications for Parkinson disease.
Spina, M. B., & Cohen, G. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1398 · Cited by 395
Self-citationFree Radicals in Medicine. I. Chemical Nature and Biologic Reactions
SOUTHORN, P. A., & POWIS, G. (1988) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)64861-7 · Cited by 392
Perry, T. L., & Yong, V. W. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90320-4 · Cited by 361
Parkinson's disease in 65 pairs of twins and in a set of quadruplets
Ward, C. D., Duvoisin, R. C., Ince, S. E., Nutt, J. D., Eldridge, R., & Calne, D. B. (1983) · Neurology · doi:10.1212/wnl.33.7.815 · Cited by 348
Epidemiology of parkinsonism: Incidence, classification, and mortality
Rajput, A. H., Offord, K. P., Beard, C. M., & Kurland, L. T. (1984) · Annals of Neurology · doi:10.1002/ana.410160303 · Cited by 340
Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
Michel, P. P., & Hefti, F. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490260405 · Cited by 338
Carlsson, A., & Winblad, B. (1976) · Journal of Neural Transmission · doi:10.1007/bf01249444 · Cited by 330
Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., & Minakami, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90498-c · Cited by 319
Glutathione peroxidase activity in Parkinson's disease brain
Kish, S. J., Morito, C., & Hornykiewicz, O. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90078-3 · Cited by 299
Youdim, M. B. H., Ben-Shachar, D., & Riederer, P. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb01782.x · Cited by 292
Hökfelt, T., & Ungerstedt, U. (1973) · Brain Research · doi:10.1016/0006-8993(73)90791-9 · Cited by 292
Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease
Hattori, N., Tanaka, M., Ozawa, T., & Mizuno, Y. (1991) · Annals of Neurology · doi:10.1002/ana.410300409 · Cited by 276
Oxygen Free Radicals and Brain Dysfunction
Jesberger, J. A., & Richardson, J. S. (1991) · International Journal of Neuroscience · doi:10.3109/00207459109150342 · Cited by 273
6-Hydroxydopamine: Evidence for Superoxide Radical as an Oxidative Intermediate
Heikkila, R. E., & Cohen, G. (1973) · Science · doi:10.1126/science.181.4098.456 · Cited by 259
Self-citationDecreased ferritin levels in brain in Parkinson's disease
Dexter, D. T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., Lees, A. J., Wells, F. R., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb08814.x · Cited by 258
Oxygen toxicity protecting enzymes in Parkinson's disease
Marttila, R. J., Lorentz, H., & Rinne, U. K. (1988) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(88)90108-6 · Cited by 249
Oxidation reactions in Parkinson's disease.
Olanow, C. W. (1990) · PubMed · Cited by 245
The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Cohen, G. (1983) · PubMed · Cited by 226
Self-citationOn the origin and significance of neuromelanin.
Dg, G. (1979) · PubMed · Cited by 223
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
Cohen, G., & Spina, M. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260518 · Cited by 211
Self-citationPossible role of neuromelanin in the pathogenesis of Parkinson's disease
MANN, D., & YATES, P. (1983) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(83)90074-x · Cited by 211
Oxidative stress as a cause of Parkinson's disease
Jenner, P., & Jenner, P. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb05013.x · Cited by 205
Marshall, J. F., & Ungerstedt, U. (1977) · European Journal of Pharmacology · doi:10.1016/0014-2999(77)90256-4 · Cited by 202
Environmental Factors in the Etiology of Parkinson's Disease
Tanner, C. M., Chen, B., Wang, W.-Z., Peng, M.-L., Liu, Z.-L., Liang, X.-L., Kao, L. C., Gilley, D. W., & Schoenberg, B. S. (1987) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100037835 · Cited by 184
Selegiline as initial treatment in de novo parkinsonian patients
Myllylä, V. V., Sotaniemi, K. A., Vuorinen, J. A., & Heinonen, E. H. (1992) · Neurology · doi:10.1212/wnl.42.2.339 · Cited by 171
CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN
Faux, J. A., Byron, M. A., & Chapel, H. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92069-2 · Cited by 165
Reduced and oxidized glutathione in human and monkey brain
Slivka, A., Spina, M. B., & Cohen, G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90061-9 · Cited by 162
Self-citationBerger, K., Przedborski, S., & Cadet, J. L. (1991) · Brain Research Bulletin · doi:10.1016/0361-9230(91)90242-c · Cited by 153
In Vivo Autoxidation of Dopamine in Guinea Pig Striatum Increases with Age
Fornstedt, B., Pileblad, E., & Carlsson, A. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04183.x · Cited by 143
The Epidemiology of Parkinson's Disease: A Case-Control Study of Young-Onset and Old-Onset Patients
Stern, M. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530210029018 · Cited by 139
Dopa and dopamine cause cultured neuronal death in the presence of iron
Tanaka, M., Sotomatsu, A., Kanai, H., & Hirai, S. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90046-a · Cited by 139
Neurotoxicity of levodopa on catecholamine‐rich neurons
Mena, M. A., Pardo, B., Casarejos, M. J., Fahn, S., & de Yébenes, J. G. (1992) · Movement Disorders · doi:10.1002/mds.870070105 · Cited by 137
Self-citationNormal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect
Lestienne, P., Nelson, J., Riederer, P., Jellinger, K., & Reichmann, H. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04973.x · Cited by 131
Perry, T. L., Yong, V. W., Ito, M., Foulks, J. G., Wall, R. A., Godin, D. V., & Clavier, R. M. (1984) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1984.tb12834.x · Cited by 131
Twin studies and the genetics of Parkinson's disease—a reappraisal
Johnson, W. G., Hodge, S. E., & Duvoisin, R. C. (1990) · Movement Disorders · doi:10.1002/mds.870050302 · Cited by 130
Could Parkinson's disease follow intra-uterine influenza?: a speculative hypothesis.
Mattock, C., Marmot, M., & Stern, G. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.753 · Cited by 128
Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouse
Hefti, F., Melamed, E., Bhawan, J., & Wurtman, R. J. (1981) · Neurology · doi:10.1212/wnl.31.9.1194 · Cited by 126
Cohort analysis of Parkinson's syndrome
Poskanzer, D. C., & Schwab, R. S. (1963) · Journal of Chronic Diseases · doi:10.1016/0021-9681(63)90098-5 · Cited by 121
Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons
Steece‐Collier, K., Collier, T. J., Sladek, C. D., & Sladek, J. R. (1990) · Experimental Neurology · doi:10.1016/0014-4886(90)90031-m · Cited by 120
Blunt, S. B., Jenner, P., & Marsden, C. D. (1993) · Movement Disorders · doi:10.1002/mds.870080202 · Cited by 115
Cohen, G., Heikkila, R. E., Allis, B., Cabbat, F., Dembiec, D., MacNamee, D., Mytilineou, C., & Winston, B. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30688-9 · Cited by 113
Self-citationMitochondrial DNA analysis in Parkinson's disease
Schapira, A. H. V., Holt, I. J., Sweeney, M., Harding, A. E., Jenner, P., & Marsden, C. D. (1990) · Movement Disorders · doi:10.1002/mds.870050406 · Cited by 112
Semchuk, K. M., Love, E. J., & Lee, R. G. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100031826 · Cited by 108
Brain iron : neurochemical and behavioural aspects
Youdim, M. B. H. (1988) · Taylor & Francis eBooks · Cited by 102
Exposure of school synaptosomes to L-dopa increases levels of oxidized glutathione.
Spina, M. B., & Cohen, G. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13392-2 · Cited by 98
Self-citationExposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.
Spina, M. B., & Cohen, G. (1988) · PubMed · Cited by 77
Self-citationDemonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique
Konradi, C. L., Kornhuber, J., Froelich, L., Fritze, J., Heinsen, H., Beckmann, H., Schulz, E., & Riederer, P. F. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90218-2 · Cited by 77
Yurek, D. M., Steece‐Collier, K., Collier, T. J., & Sladek, J. R. (1991) · Experimental Brain Research · doi:10.1007/bf00231044 · Cited by 75
Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease
Rinne, J. O., Röyttä, M., Paljärvi, L., Rummukainen, J. K., & Rinne, U. K. (1991) · Neurology · doi:10.1212/wnl.41.6.859 · Cited by 61
Fahn, S. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb14919.x · Cited by 60
Self-citationMonoamine oxidase, dopamine and Parkinson's disease
Oreland, L. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb05021.x · Cited by 47
The low concordance rate for Parkinson's disease in twins
Eldridge, R., & Ince, S. E. (1984) · Neurology · doi:10.1212/wnl.34.10.1354 · Cited by 40
Biochemical changes in normal aging in human brain.
Cote, L. J., & Kremzner, L. T. (1983) · PubMed · Cited by 39
Aisen, P., COHEN, G., & KANG, J. O. (1990) · International review of experimental pathology · doi:10.1016/b978-0-12-364931-7.50006-9 · Cited by 32
Self-citationThe Clinical Syndrome of Striatal Dopamine Deficiency: Parkinsonism Induced by MPTP
Eldridge, R., & Rocca, W. A. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131813 · Cited by 29
Langston, J. W. (1989) · Movement Disorders · doi:10.1002/mds.870040504 · Cited by 26
Carvey, P. M., Ptak, L. R., Lo, E. S., Lin, D., Buhrfiend, C. M., Goetz, C. G., & Klawans, H. L. (1991) · Experimental Neurology · doi:10.1016/0014-4886(91)90081-m · Cited by 22
Research works printed but not linked: 6
- Duvoisin RC, 1982, Movement disorders, 8
- 10.1212/wnl.35.7.949 · DOI · Paper page
- Langston JW, 1987, Movement disorders 2, 73
- 10.1073/pnas.86.4.1398 · DOI · Paper page
- Brody H, 1976, Neurobiology of aging, 177
- Hornykiewicz O, 1982, Movement disorders, 41
Cited by
The Free Radical Theory of Aging Matures
BECKMAN, K. B., & AMES, B. N. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.2.547 · Cited by 3,879
Oxidative Stress, Glutamate, and Neurodegenerative Disorders
Coyle, J. T., & Puttfarcken, P. (1993) · Science · doi:10.1126/science.7901908 · Cited by 3,762
Mitochondrial free radical generation, oxidative stress, and aging
Cadenas, E., & Davies, K. J. A. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00317-8 · Cited by 3,010
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
“However, overall there is sufficient evidence to support the concept that oxidative stress occurs in substantia nigra in PD and that it contributes to nigral cell degeneration.(69) Potential pro-oxidant actions of L-dopa have added to the debate over the role of oxidative stress in PD and its role in disease progressi…”
BackgroundDilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase
Li, Y., Huang, T.-T., Carlson, E. J., Melov, S., Ursell, P. C., Olson, J. L., Noble, L. J., Yoshimura, M. P., Berger, C., Chan, P. H., et al. (1995) · Nature Genetics · doi:10.1038/ng1295-376 · Cited by 1,789
Metadata
- Authors
- Fahn, S., & Cohen, G.
- Affiliations
- Columbia University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Fahn, Stanley
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1992-12
- Volume
- 32
- Issue
- 6
- Pages
- 804-812
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2052548407
- Cited by
- 927
- References
- 89
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 10 · 2023: 14 · 2022: 9 · 2021: 21 · 2020: 22 · 2019: 13 · 2018: 15 · 2017: 21 · 2016: 18 · 2015: 13 · 2014: 20 · 2013: 25 · 2012: 29
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, oxidative stress, substantia nigra, dopaminergic neurons, lipid peroxidation, hydrogen peroxide, oxygen free radicals, dopamine autoxidation, iron, ferritin, neuromelanin, antioxidant defense, glutathione, superoxide dismutase, MPTP-induced neurotoxicity, 6-hydroxydopamine, monoamine oxidase
- MeSH terms
- Animals, Free Radicals, Humans, Oxidation-Reduction, Parkinson Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.